Cite
Beitzen-Heineke A, Berenbrok N, Waizenegger J, et al. AXL Inhibition Represents a Novel Therapeutic Approach in . Hemasphere. 2021;5(9):e630doi: 10.1097/HS9.0000000000000630.
Beitzen-Heineke, A., Berenbrok, N., Waizenegger, J., Paesler, S., Gensch, V., Udonta, F., Vargas Delgado, M. E., Engelmann, J., Hoffmann, F., Schafhausen, P., von Amsberg, G., Riecken, K., Beumer, N., Imbusch, C. D., Lorens, J., Fischer, T., Pantel, K., Bokemeyer, C., Ben-Batalla, I., & Loges, S. (2021). AXL Inhibition Represents a Novel Therapeutic Approach in . HemaSphere, 5(9), e630. https://doi.org/10.1097/HS9.0000000000000630
Beitzen-Heineke, Antonia, et al. "AXL Inhibition Represents a Novel Therapeutic Approach in ." HemaSphere vol. 5,9 (2021): e630. doi: https://doi.org/10.1097/HS9.0000000000000630
Beitzen-Heineke A, Berenbrok N, Waizenegger J, Paesler S, Gensch V, Udonta F, Vargas Delgado ME, Engelmann J, Hoffmann F, Schafhausen P, von Amsberg G, Riecken K, Beumer N, Imbusch CD, Lorens J, Fischer T, Pantel K, Bokemeyer C, Ben-Batalla I, Loges S. AXL Inhibition Represents a Novel Therapeutic Approach in . Hemasphere. 2021 Aug 11;5(9):e630. doi: 10.1097/HS9.0000000000000630. eCollection 2021 Sep. PMID: 34396051; PMCID: PMC8357258.
Copy
Download .nbib